Pharmaceuticals, Biotechnology and Life Sciences
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its sale of its Xiidra® (lifitegrast ophthalmic solution) 5% product to Novartis for $3.4 billion upfront in cash and up to an additional $1.9 billion in potential milestone payments.
Takeda’s founding mission to serve patients, wherever they are, drives its increased commitments to disease prevention, capacity building, and access to healthcare in developing and emerging countries, in partnership with the global community.
The “Takeda Chair in Global Child Health” is the first Chair at the London School of Hygiene & Tropical Medicine…
Takeda sells Xiidra to Novartis for up to$5.3 billion, TachoSil to Ethicon for approximately $400 million
New facility focuses on specialized drug discovery technologies and discovery research across gastrointestinal and neuroscience therapeutic areas SAN DIEGO–(BUSINESS WIRE)–Takeda…
Additional treatment modality would provide greater choice in how patients receive gut-selective biologic vedolizumab Vedolizumab set to be the only…
Impact on patient quality of life quantified including long-term renal and cardiovascular complications Final outcomes of 6 year study into…
– Takeda obtains rights to LCB’s ADC platfo–LegoChem Biosciences, Inc. (“LCB”) (KOSDAQ:141080) announced today that it has entered a research…
FLEXBUMIN 25% [Albumin (Human)], USP, 25% Solution is indicated for hypovolemia, hypoalbuminemia, (burns, Adult Respiratory Distress Syndrome (ARDS), and nephrosis),…
TiGenix NV’s Chief Executive Officer, Eduardo Bravo will depart the board of directors and his role as CEO of TiGenix…